Skip to main content
Clinical studies· 5 min read

More than 4,000 patients: what the hPG80 studies show

26 clinical studies, 4,045 patient samples and 1,199 samples from healthy volunteers.¹

Where the figure of 4,000 patients comes from

The pooled data come from 26 case-control clinical studies: 22 retrospective and four prospective. These studies compare people with cancer with healthy people.¹

A female researcher reviewing study data
26 clinical studies brought together to compare hPG80 levels.

They include nearly 1,200 healthy volunteers with no symptoms, representing 1,199 samples, and more than 4,000 patients with 16 types of cancer, representing 4,045 samples.¹

The median hPG80 level is 1.5 pmol/L in healthy people, compared with 4.6 pmol/L in patients with cancer, across all stages.¹

Median hPG80 level by cancer stage

pmol/L

Detection threshold (intermediate): 3.3 pmol/L (intermediate threshold; high levels above 10,90 pmol/L)
Healthy individuals
n = 1 199
Stage I
n = 390
Stage II
n = 374
Stage III
n = 284
Stage IV
n = 1 581
hPG80 levels are already higher at stage I and remain higher at every stage. Above 3.3 pmol/L, the level is considered intermediate; above 10.9 pmol/L, it is considered high.¹
Number of patients by cancer type¹
CancerPatients
Lung829
Breast712
Prostate608
Colorectal373
Gynaecological302
Liver300
Kidney232
Oesophagus/stomach137
Skin melanoma133
Neuroendocrine129
Pancreas108
Brain102
Head and neck49
Eye melanoma31

The foundational study (EBioMedicine, 2020)

The foundational study compares 1,546 patients with 11 types of cancer with 557 healthy blood donors. The cancers studied are breast, uterine, ovarian, prostate, kidney, colorectal, pancreatic, oesophageal/stomach and liver cancer, cutaneous melanoma and lung cancer.²

Sample tubes arranged on a laboratory bench
A marker measured in the blood and monitoring during treatment.

The median hPG80 level is 4.88 pmol/L in patients, compared with 1.05 pmol/L in donors. Depending on the cancer type, it ranges from 2.50 pmol/L for breast cancer to 11.65 pmol/L for liver cancer.²

Monitoring during treatment shows a decrease in levels after surgery in most patients. A decrease of more than 25% is observed in 74% of the patients followed.²

In liver cancer, the median level is 1.99 pmol/L during remission, compared with 15.71 pmol/L when the disease is active. These findings describe how the marker changes during treatment and disease follow-up.²

The prospective ONCOPRO study (Biomarker Research, 2025)

The prospective ONCOPRO study, conducted at Hospices Civils de Lyon and registered under NCT03787056, enrolled 506 patients between 2018 and 2022.³

Of these, 421 patients across 16 cancer types could be included in the analysis. They were compared with 330 healthy people.³

The median hPG80 level is 3.8 pmol/L in patients, compared with 1.9 pmol/L in healthy people. This large prospective study confirms substantially higher levels in patients with cancer.³

What this means for you

  • Levels are higher in many cancers, including at the earliest stages.¹²³
  • A high level is a signal that calls for further examinations, not a medical conclusion on its own.¹²³
  • That is why a doctor always explains the result.¹²³
Prevonco

Prevonco is currently available in France only.

An aid to the early detection of 16 cancers

No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.

Pre-register for free →